Literature DB >> 29397459

Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review.

Mathilde Leclercq1, M Le Besnerais2, V Langlois3, N Girszyn4, Y Benhamou2, C Ngo5, H Levesque2, M Muraine5, J Gueudry5.   

Abstract

Biotherapies appear as potential drugs for the treatment of inflammatory noninfectious uveitis. In this report, we show that tocilizumab, an anti-IL-6 agent, greatly improved two patients with birdshot chorioretinopathy refractory to conventional immunosuppressive drugs, interferon α2a, and anti-TNFα agents. After a follow-up of 22 months, patients exhibited an improvement of both visual acuity and macular edema. A corticosteroid-sparing effect was achieved in both cases.

Entities:  

Keywords:  Birdshot chorioretinopathy; Interferon α2a; Macular edema; Tocilizumab

Mesh：

Substances：

Year:  2018        PMID： 29397459     DOI： 10.1007/s10067-018-4007-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  20 in total

1.  Tocilizumab in severe and refractory non-infectious uveitis.

Authors:  Matthias Papo; Philip Bielefeld; Hélène Vallet; Pascal Seve; Bertrand Wechsler; Patrice Cacoub; Phuc Le Hoang; Thomas Papo; Bahram Bodaghi; David Saadoun
Journal:  Clin Exp Rheumatol       Date:  2014-09-30       Impact factor: 4.473

2.  Regulatory T cells in blood of patients with birdshot retinochoroidopathy.

Authors:  C Stephen Foster; Sana S Siddique; Laura Amorese; Lama Mulki; Ana Suelves
Journal:  Ophthalmology       Date:  2013-02       Impact factor: 12.079

3.  Outcome of tocilizumab treatment in refractory ocular inflammatory diseases.

Authors:  Sukhum Silpa-Archa; Merih Oray; Janine M Preble; Charles Stephen Foster
Journal:  Acta Ophthalmol       Date:  2016-03-24       Impact factor: 3.761

4.  Adalimumab in Patients with Active Noninfectious Uveitis.

Authors:  Glenn J Jaffe; Andrew D Dick; Antoine P Brézin; Quan Dong Nguyen; Jennifer E Thorne; Philippe Kestelyn; Talin Barisani-Asenbauer; Pablo Franco; Arnd Heiligenhaus; David Scales; David S Chu; Anne Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Eric B Suhler
Journal:  N Engl J Med       Date:  2016-09-08       Impact factor: 91.245

5.  [Effectiveness of interferon alpha in the treatment of uveitis macular edema refractory to corticosteroid and/or immunosuppressive treatment].

Authors:  V Paire; O Lebreton; M Weber
Journal:  J Fr Ophtalmol       Date:  2010-02-24       Impact factor: 0.818

6.  Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis.

Authors:  Aurore Muselier; Philip Bielefeld; Samuel Bidot; Julien Vinit; Jean-François Besancenot; Alain Bron
Journal:  Ocul Immunol Inflamm       Date:  2011-10       Impact factor: 3.070

Review 7.  Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review.

Authors:  Vanesa Calvo-Río; Ricardo Blanco; Montserrat Santos-Gómez; David Díaz-Valle; Esperanza Pato; Javier Loricera; María C González-Vela; Rosalía Demetrio-Pablo; José L Hernández; Miguel A González-Gay
Journal:  Ocul Immunol Inflamm       Date:  2016-10-11       Impact factor: 3.070

8.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Peter M Villiger; Sabine Adler; Stefan Kuchen; Felix Wermelinger; Diana Dan; Veronika Fiege; Lukas Bütikofer; Michael Seitz; Stephan Reichenbach
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

Review 9.  Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment.

Authors:  Evangelos Minos; Robert J Barry; Sue Southworth; Annie Folkard; Philip I Murray; Jay S Duker; Pearse A Keane; Alastair K Denniston
Journal:  Orphanet J Rare Dis       Date:  2016-05-12       Impact factor: 4.123

Review 10.  Birdshot uveitis: current and emerging treatment options.

Authors:  Victor Menezo; Simon Rj Taylor
Journal:  Clin Ophthalmol       Date:  2013-12-18
View more
  6 in total

1.  [White dot syndromes : Principles, diagnostics, and treatment].

Authors:  Dominika Pohlmann; Sibylle Winterhalter; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2019-12       Impact factor: 1.059

Review 2.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

Review 3.  Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges.

Authors:  Horace Massa; Spyros Y Pipis; Georgios D Panos; Temilade Adewoyin; Athanasios Vergados; Sudeshna Patra
Journal:  Clin Ophthalmol       Date:  2019-09-10

Review 4.  Birdshot Chorioretinopathy: A Review.

Authors:  Elodie Bousquet; Pierre Duraffour; Louis Debillon; Swathi Somisetty; Dominique Monnet; Antoine P Brézin
Journal:  J Clin Med       Date:  2022-08-16       Impact factor: 4.964

Review 5.  SARS-CoV-2 vaccination and uveitis: Are they linked?

Authors:  Summaiyya Waseem; Syed Hassan Ahmed; Sharmeen Fatima; Taha Gul Shaikh; Jawad Ahmed
Journal:  Ann Med Surg (Lond)       Date:  2022-08-28

Review 6.  Biotherapies in Uveitis.

Authors:  Mathilde Leclercq; Anne-Claire Desbois; Fanny Domont; Georgina Maalouf; Sara Touhami; Patrice Cacoub; Bahram Bodaghi; David Saadoun
Journal:  J Clin Med       Date:  2020-11-08       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.